Redhawk Wealth Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.27M Sell
6,057
-201
-3% -$205K 0.72% 38
2026
Q1
$5.76M Sell
6,258
-1,478
-19% -$1.5M 0.64% 35
2025
Q4
$8.31M Buy
7,736
+13
+0.2% +$12.4K 0.93% 27
2025
Q3
$5.89M Buy
7,723
+509
+7% +$379K 0.68% 35
2025
Q2
$5.62M Buy
7,214
+176
+3% +$137K 0.71% 35
2025
Q1
$5.81M Buy
7,038
+170
+2% +$141K 0.78% 29
2024
Q4
$5.3M Buy
6,868
+313
+5% +$259K 0.72% 32
2024
Q3
$5.81M Sell
6,555
-146
-2% -$131K 0.83% 31
2024
Q2
$6.07M Sell
6,701
-294
-4% -$235K 0.93% 24
2024
Q1
$5.44M Buy
6,995
+583
+9% +$415K 0.89% 27
2023
Q4
$3.74M Sell
6,412
-574
-8% -$335K 0.73% 37
2023
Q3
$3.75M Buy
6,986
+65
+0.9% +$33.5K 1.25% 19
2023
Q2
$3.25M Buy
6,921
+120
+2% +$50.3K 0.99% 20
2023
Q1
$2.34M Buy
6,801
+84
+1% +$28.3K 0.79% 30
2022
Q4
$2.46M Buy
6,717
+2,998
+81% +$1.06M 0.95% 25
2022
Q3
$1.2M Buy
3,719
+156
+4% +$49.4K 0.51% 44
2022
Q2
$1.16M Buy
+3,563
New +$1.07M 0.52% 40

Other funds holding LLY

Redhawk Wealth Advisors's LLY Position: Q2 2026 in Review

Redhawk Wealth Advisors reduced its Eli Lilly (LLY) stake by 3.2% in Q2 2026, selling an estimated $205K and leaving 6,057 shares worth $7.27M. The position accounts for 0.72% of the portfolio, ranked #38.

Redhawk Wealth Advisors first reported a position in LLY in Q2 2022 and has held it in 17 quarters since. The position peaked at $8.31M in Q4 2025. 950 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Redhawk Wealth Advisors held 6,057 shares of Eli Lilly worth $7.27M as of Q2 2026.
  • Redhawk Wealth Advisors sold 201 Eli Lilly shares in Q2 2026, an estimated $205K.
  • Eli Lilly made up 0.72% of Redhawk Wealth Advisors's portfolio in Q2 2026, its #38 holding.
  • Redhawk Wealth Advisors first reported a position in Eli Lilly in Q2 2022 and has held it in 17 quarters since.
  • Redhawk Wealth Advisors's Eli Lilly position peaked at $8.31M in Q4 2025.
  • 950 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Redhawk Wealth Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.